1yy8: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
[[Image:1yy8.gif|left|200px]] | [[Image:1yy8.gif|left|200px]] | ||
'''Crystal structure of the Fab fragment from the monoclonal antibody cetuximab/Erbitux/IMC-C225''' | {{Structure | ||
|PDB= 1yy8 |SIZE=350|CAPTION= <scene name='initialview01'>1yy8</scene>, resolution 2.00Å | |||
|SITE= | |||
|LIGAND= | |||
|ACTIVITY= | |||
|GENE= | |||
}} | |||
'''Crystal structure of the Fab fragment from the monoclonal antibody cetuximab/Erbitux/IMC-C225''' | |||
==Overview== | ==Overview== | ||
Line 7: | Line 16: | ||
==About this Structure== | ==About this Structure== | ||
1YY8 is a [ | 1YY8 is a [[Protein complex]] structure of sequences from [http://en.wikipedia.org/wiki/Mus_musculus/homo_sapiens Mus musculus/homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1YY8 OCA]. | ||
==Reference== | ==Reference== | ||
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab., Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM, Cancer Cell. 2005 Apr;7(4):301-11. PMID:[http:// | Structural basis for inhibition of the epidermal growth factor receptor by cetuximab., Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM, Cancer Cell. 2005 Apr;7(4):301-11. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/15837620 15837620] | ||
[[Category: Mus musculus/homo sapiens]] | [[Category: Mus musculus/homo sapiens]] | ||
[[Category: Protein complex]] | [[Category: Protein complex]] | ||
Line 21: | Line 30: | ||
[[Category: fab fragment; antibody drug; cancer]] | [[Category: fab fragment; antibody drug; cancer]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Mar 20 15:28:59 2008'' |
Revision as of 16:29, 20 March 2008
| |||||||
, resolution 2.00Å | |||||||
---|---|---|---|---|---|---|---|
Coordinates: | save as pdb, mmCIF, xml |
Crystal structure of the Fab fragment from the monoclonal antibody cetuximab/Erbitux/IMC-C225
OverviewOverview
Recent structural studies of epidermal growth factor receptor (EGFR) family extracellular regions have identified an unexpected mechanism for ligand-induced receptor dimerization that has important implications for activation and inhibition of these receptors. Here we describe the 2.8 angstroms resolution X-ray crystal structure of the antigen binding (Fab) fragment from cetuximab (Erbitux), an inhibitory anti-EGFR antibody, in complex with the soluble extracellular region of EGFR (sEGFR). The sEGFR is in the characteristic "autoinhibited" or "tethered" inactive configuration. Cetuximab interacts exclusively with domain III of sEGFR, partially occluding the ligand binding region on this domain and sterically preventing the receptor from adopting the extended conformation required for dimerization. We suggest that both these effects contribute to potent inhibition of EGFR activation.
About this StructureAbout this Structure
1YY8 is a Protein complex structure of sequences from Mus musculus/homo sapiens. Full crystallographic information is available from OCA.
ReferenceReference
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab., Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM, Cancer Cell. 2005 Apr;7(4):301-11. PMID:15837620
Page seeded by OCA on Thu Mar 20 15:28:59 2008